Arvinas Inc

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

– Enrollment continues in the 2L Phase 3 VERITAC-2 trial and study lead-in for the VERITAC-3 1L Phase 3 trial with vepdegestrant; Top-line data readout for VERITAC-2 remains on-track for 2H 2024 –

Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Arvinas, Inc. (ARVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in Arvinas, Inc. (ARVN): Can Its 6.3% Jump Turn into More Strength?

– Data presented at the European Society for Medical Oncology from the Phase 1/2 trial with bavdegalutamide showed 11.1 months radiographic progression free survival in mCRPC patients with tumors harboring AR 878/875 mutations –

Potential of Arvinas' PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC

NEW HAVEN, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that nearly 200 employees participated in the Company's second annual “Arvinas Impact Day,” a company-wide community service day benefiting organizations in the Greater New Haven area.

Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day

NEW HAVEN, Conn., Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it will present updated Phase 1/2 trial data for bavdegalutamide (ARV-110) at the 2023 European Society for Medical Oncology (ESMO) Annual Congress. Bavdegalutamide is an investigational orally bioavailable PROTAC® androgen receptor (AR) degrader and is being developed as a potential treatment for men with metastatic castration-resistant prostate cancer (mCRPC). This update will be presented during a poster session at the annual congress being held from October 20-24, 2023, in Madrid, Spain.

Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023

NEW HAVEN, Conn. and NEW YORK, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated Phase 1/2 data for vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology (ESMO) Annual Congress. Vepdegestrant is a novel oral PROTAC® estrogen receptor (ER) degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with locally advanced or metastatic ER positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer. This update will be presented during a poster session at the annual congress being held from October 20-24, 2023, in Madrid, Spain.

Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023

Arvinas focuses on protein degradation therapies, with current projects targeting breast and prostate cancers. Financially, ARVU holds robust liquidity, minimal debt, and a cash runway till 2026; combined with encouraging preliminary therapeutic results. Given Arvinas' solid financials and promising therapy potential, the investment recommendation is 'Buy' for risk-tolerant, biotechnology-focused investors.

Arvinas' Potential In Treating ER+, HER2- Breast Cancer

– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471), including VERITAC-2 2L Phase 3 trial and study lead-in for the VERITAC-3 1L Phase 3 trial, both in ER+/HER2- metastatic breast cancer –

Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Designation indicates entry into the U.K.'s Innovative Licensing and Access Pathway (ILAP) Designation indicates entry into the U.K.'s Innovative Licensing and Access Pathway (ILAP)

Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast Cancer

NEW HAVEN, Conn., June 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Timothy Shannon, M.D., current Chairperson and a member of the company's Board of Directors since 2013, has stepped down from this role. John Houston, Ph.D., has been named Chairperson, effective today. Additionally, Sunil Agarwal, M.D., has been appointed to join the company's Board and Briggs Morrison, M.D., has been appointed Lead Independent Director of the Board.

Arvinas Announces Changes to its Board of Directors

Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Arvinas, Inc. (ARVN) Moves 17.5% Higher: Will This Strength Last?

Arvinas, Inc. has exciting science, but data has been a disappointment. There are no near-term major catalysts for Arvinas. Arvinas has a lot of cash, and is trading nearly at cash.

Arvinas: Nothing Interesting In The Near Term

– 42% of patients with AR ligand binding domain (LBD) mutations achieved PSA 50 ; in patients with AR L702H mutations, 3 of 5 achieved PSA 50 –

Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations

NEW HAVEN, Conn. and NEW YORK, May 08, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated data related to vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress. Vepdegestrant is a novel investigational PROTAC® estrogen receptor (ER) protein degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with early and locally advanced or metastatic ER positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer. Four posters will be presented during the poster session at the annual congress, which will be held from May 11-13, 2023, in Berlin, Germany.

Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

Arvinas, Inc. (ARVN) came out with a quarterly loss of $1.54 per share versus the Zacks Consensus Estimate of a loss of $1.46. This compares to loss of $1.20 per share a year ago.

Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates

–Multiple vepdegestrant (ARV-471) studies enrolling globally, including Phase 1, 2, and 3 studies– – Preliminary data from the Phase 1b combination trial of vepdegestrant + palbociclib suggests potential clinical benefit in a heavily pretreated patient population – NEW HAVEN, Conn., May 05, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., May 03, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Sean Cassidy, Chief Financial Officer, and Randy Teel, Ph.D., Senior Vice President, Corporate and Business Development, will participate in a fireside chat at the Bank of America Securities 2023 Healthcare Conference on Tuesday, May 9 at 6:40 p.m. ET/3:40 p.m. PT in Las Vegas.

Arvinas to Present at the Bank of America Securities 2023 Healthcare Conference

NEW HAVEN, Conn. and SAN FRANCISCO , May 2, 2023 /PRNewswire/ -- Arvinas, Inc. (Nasdaq: ARVN) and Quantum Leap Healthcare Collaborative™ today announced that Arvinas' vepdegestrant (ARV-471), a novel PROTAC® estrogen receptor (ER) protein degrader being co-developed with Pfizer Inc. will be evaluated in the ongoing I-SPY TRIAL endocrine program sponsored by Quantum Leap.

Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical Trial

NEW HAVEN, Conn., April 21, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, and Sean Cassidy, Chief Financial Officer, will participate in a fireside at the Stifel Targeted Oncology Day on Wednesday, April 26 at 11:30 a.m. ET.

Arvinas to Present at Stifel Targeted Oncology Day

Arvinas, Inc. (ARVN) Surges 7.6%: Is This an Indication of Further Gains?

NEW HAVEN, Conn., April 03, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Kelly Page has joined the company as Senior Vice President, Global Head of Oncology Strategy and Program Leadership.

Arvinas Appoints Kelly Page as Senior Vice President, Global Head of Oncology Strategy and Program Leadership

Arvinas' PROTAC approach has several advantages over conventional drugs, including the potential to target "undruggable" proteins, achieve tissue-specific targeting, and cross the blood-brain barrier. The company has three lead products in clinical trials for target hormone-dependent cancers such as prostate and breast cancer.

Arvinas: PROTAC Platform Shows Promise In Clinical Trials For Oncology Indications

– Initiated multiple trials with ARV-471, including a 2L+ Phase 3 trial for patients with  metastatic breast cancer –

Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Rocket Pharma

Xencor

Health care stocks are trying to make a comeback and these three small-cap biopharma companies are leading the charge in some ways.

3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023

Arvinas, Inc. (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

News for Arvinas Inc Stock (ARVN)